ストックスクリーナーアプリを入手
5.28
1.86%
-0.10
前日終値:
$5.38
開ける：
$5.38
24時間の取引高:
2.34M
Relative Volume:
0.59
時価総額：
$1.30B
収益：
$427.68M
当期純損益:
$-58.06M
株価収益率:
-22.17
EPS:
-0.2382
ネットキャッシュフロー:
$-37.50M
1週間 パフォーマンス:
+0.19%
1か月 パフォーマンス:
-5.88%
6か月 パフォーマンス:
-31.78%
1年 パフォーマンス:
+12.34%
1日の値動き範囲:
$5.19
$5.39
1週間の範囲:
$5.15
$5.56
52週間の値動き範囲:
$4.075
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Compare ARDX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.28 | 1.30B | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-09 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-09-03 | 再開されました | Raymond James | Strong Buy |
| 2025-06-18 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-02 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | 再開されました | Ladenburg Thalmann | Buy |
| 2025-03-04 | 開始されました | BTIG Research | Buy |
| 2024-11-11 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | 開始されました | Leerink Partners | Outperform |
| 2023-12-18 | 開始されました | Raymond James | Strong Buy |
| 2023-09-07 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-25 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-11-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | ダウングレード | Jefferies | Buy → Hold |
| 2021-07-20 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-03-23 | 開始されました | Wedbush | Outperform |
| 2021-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-10-20 | 再開されました | Citigroup | Buy |
| 2020-02-18 | 再開されました | Jefferies | Buy |
| 2020-02-12 | 開始されました | Citigroup | Buy |
| 2020-02-10 | 開始されました | Cowen | Outperform |
| 2019-04-08 | 開始されました | Piper Jaffray | Overweight |
| 2018-08-24 | 開始されました | Jefferies | Buy |
| 2018-03-19 | 再開されました | Leerink Partners | Outperform |
| 2017-11-29 | 繰り返されました | Citigroup | Buy |
| 2017-11-22 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2017-10-17 | 再開されました | Leerink Partners | Outperform |
| 2016-03-31 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-03-09 | 開始されました | Cantor Fitzgerald | Buy |
| 2016-03-03 | 開始されました | Citigroup | Buy |
すべてを表示
Ardelyx Inc (ARDX) 最新ニュース
Lobbying Update: $20,000 of ARDELYX INC lobbying was just disclosed - Quiver Quantitative
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Ardelyx (NASDAQ: ARDX) draws $50M Term F loan maturing in 2030 - Stock Titan
Ardelyx: The Market Is Right To Discount This Revenue Growth - Seeking Alpha
Price to book forward of Ardelyx, Inc. – NASDAQ:ARDX - TradingView
Price to sales forward of Ardelyx, Inc. – NASDAQ:ARDX - TradingView
Price to earnings forward of Ardelyx, Inc. – TRADEGATE:41X - TradingView
Ardelyx, Inc.'s (NASDAQ:ARDX) Shift From Loss To Profit - 富途牛牛
Ardelyx (ARDX) Faces New Medicare Rules For Xphozah After Court Ruling - simplywall.st
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
Ardelyx stock decline attributed to setback in Xphozah appeal - MSN
ARDX Stock Tumbles As Xphozah Loses Final Medicare Reimbursement Battle - TradingView
Ardelyx (ARDX) Faces Appeal Setback but Maintains Buy Rating - GuruFocus
Jefferies Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Ardelyx falls after setback in Xphozah appeal (ARDX:NASDAQ) - Seeking Alpha
Ardelyx Loses Appeal of HHS Reclassification of Kidney Drug - Bloomberg Law News
Ardelyx Inc (ARDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ardelyx stock trades down as mixed technical signals cap upside potential - Traders Union
ARDX Forecast — Price Target — Prediction for 2027 - TradingView
Ardelyx, Inc. Actuals & Estimates (NASDAQ:ARDX) - TradingView
Ardelyx, Inc. Actuals & Estimates (FWB:41X) - TradingView
41X Forecast — Price Target — Prediction for 2027 - TradingView
Is Ladenburg’s IBSRELA Focus Quietly Reframing Ardelyx’s (ARDX) Risk‑Reward Story? - simplywall.st
Aquestive Therapeutics (AQST) Moves 6.6% Higher: Will This Strength Last? - Yahoo! Finance Canada
Ardelyx Inc (ARDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction - The Globe and Mail
What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline? - Yahoo Finance
Ardelyx Inc (ARDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Form 4 Ardelyx Inc For: 22 June By Investing.com - Investing.com Australia
Ardelyx chief patient officer sells $490k in stock By Investing.com - Investing.com Australia
Ardelyx chief patient officer sells $490k in stock - Investing.com
Ardelyx Insider Sold Shares Worth $490,487, According to a Recent SEC Filing - marketscreener.com
Ardelyx (ARDX) Chief Patient Officer sells shares, exercises 31,000 options - Stock Titan
5 Best Low Priced Stocks to Get Rich in 2026 - Insider Monkey
Ardelyx (ARDX) director granted RSUs and 39,715-share stock option - Stock Titan
Laura A. Williams proposes sale of 31,000 shares (ARDX) - Stock Titan
Ardelyx (ARDX) director receives 26,455 RSUs and 39,715-share option - Stock Titan
Equity grants to Ardelyx (ARDX) director under compensation program - Stock Titan
Ardelyx (ARDX) director Cadoret-Manier receives RSU and option grants - Stock Titan
Ardelyx (ARDX) director receives RSUs and stock options as compensation - Stock Titan
Ardelyx Inc (ARDX) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):